Metastatic esophageal carcinoma masquerading as inflammatory breast carcinoma

被引:7
作者
Nebesio, Christy L.
Goulet, Robert J., Jr.
Helft, Paul R.
Billings, Steven D.
机构
[1] Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA
[3] Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA
[4] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA
基金
英国医学研究理事会;
关键词
D O I
10.1111/j.1365-4632.2006.03113.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A 50-year-old Caucasian woman with a history of esophageal adenocarcinoma presented with a 3-week history of right breast swelling and progressive erythema. Twenty-two months prior to presentation, she had been diagnosed with adenocarcinoma of the esophagus (T3,N1,M1a) and underwent neoadjuvant chemoradiotherapy followed by surgical resection. On physical examination, the right breast was red, swollen (40% larger than the contralateral breast), tender to palpation, and warm to the touch (Fig. 1). No mass was palpable. On the basis of the clinical findings, inflammatory breast carcinoma was suspected. A punch biopsy revealed a poorly differentiated adenocarcinoma with extensive involvement of dermal lymphatics (Fig. 2). The clinical and histologic differential diagnosis included inflammatory breast carcinoma vs. metastatic esophageal adenocarcinoma to the skin of the breast. To resolve this question, immunohistochemical stains for estrogen and progesterone receptors and CDX-2 (BioGenex, San Ramon, CA, USA) were performed. CDX-2 is an intestinal homeobox gene expressed in gastrointestinal epithelium and gastrointestinal tumors. The tumor nuclei were positive for CDX-2 but negative for both steroid receptors (Fig. 3), confirming the diagnosis of metastatic esophageal adenocarcinoma. © 2006 The International Society of Dermatology.
引用
收藏
页码:303 / 305
页数:3
相关论文
共 25 条
  • [11] Inflammatory breast cancer
    Lopez, MJ
    Porter, KA
    [J]. SURGICAL CLINICS OF NORTH AMERICA, 1996, 76 (02) : 411 - &
  • [12] CDX2 immunostaining as a gastrointestinal marker - Expression in lung carcinomas is a potential pitfall
    Mazziotta, RM
    Borczuk, AC
    Powell, CA
    Mansukhani, M
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2005, 13 (01) : 55 - 60
  • [13] MULLER JWT, 1984, FORTSCHR RONTG NEUEN, V140, P441
  • [14] METASTATIC TUMOR TO BREAST SIMULATING BILATERAL PRIMARY INFLAMMATORY CARCINOMA
    NANCE, FC
    MACVAUGH, H
    FITTS, WT
    [J]. AMERICAN JOURNAL OF SURGERY, 1966, 112 (06) : 932 - &
  • [15] Oraedu C O, 2001, Breast J, V7, P117, DOI 10.1046/j.1524-4741.2001.007002117.x
  • [16] The utility of cytokeratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma
    Ormsby, AH
    Goldblum, JR
    Rice, TW
    Richter, JE
    Gramlich, TL
    [J]. HISTOPATHOLOGY, 2001, 38 (04) : 307 - 311
  • [17] Cdx2 as a marker of epithelial intestinal differentiation in the esophagus
    Phillips, RW
    Frierson, HF
    Moskaluk, CA
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (11) : 1442 - 1447
  • [18] Povoski Stephen P, 2003, Breast J, V9, P497, DOI 10.1046/j.1524-4741.2003.09615.x
  • [19] Cdx1 and Cdx2 expression during intestinal development
    Silberg, DG
    Swain, GP
    Suh, ER
    Traber, PG
    [J]. GASTROENTEROLOGY, 2000, 119 (04) : 961 - 971
  • [20] Metastatic adenocarcinoma of the esophagus to the skin: new patterns of tumor recurrence and alternate treatments for palliation
    Smith, KJ
    Williams, J
    Skelton, H
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2001, 28 (08) : 425 - 431